This book collects and reviews, for the first time, a wide range of advances in the area of human aging biomarkers. This accumulated data allows researchers to assess the rate of aging processes in various organs and systems, and to individually monitor the effectiveness of therapies intended to slow aging. In an introductory chapter, the editor defines biomarkers of aging as molecular, cellular and physiological parameters that demonstrate reproducible changes - quantitative or qualitative - with age. The introduction recounts a study which aimed to create a universal model of biological age, whose most predictive parameters were albumin and alkaline phosphatase (indication liver function), glucose (metabolic syndrome), erythrocytes (respiratory function) and urea (renal function). The book goes on to describe DNA methylation, known as the "epigenetic clock," as currently the most comprehensive predictor of total mortality. It is also useful for predicting mortality from cancer and cardiovascular diseases, and for analyzing the effects of lifestyle factors including diet, exercise, and education. Individual contributions draw additional insight from research on genetics and epigenetic aging markers, and immunosenescence and inflammaging markers. A concluding chapter outlines the challenge of integrating of biological and clinical markers of aging. Biomarkers of Human Aging is written for professionals and practitioners engaged in the study of aging, and will be useful to both advanced students and researchers.

Human Aging: From Cellular Mechanisms to Therapeutic Strategies offers an exhaustive picture of all the biological aspects of human aging by describing the key mechanisms associated with human aging and covering events that could disrupt the normal course of aging. Each chapter includes a summary of the salient points covered, along with futures prospects. The book provides readers with the information they need to gain or deepen the skills needed to evaluate the mechanisms of aging and age-related diseases and to monitor the effectiveness of therapies aimed at slowing aging. The book encourages PhD and Postdoc students, researchers, health professionals and others interested in the biology of aging to explore the fascinating and challenging questions about why and how we age as well as what can and cannot be done about it. - Concentrates on different processes, e.g., oxidative stress, cellular senescence and Inflammaging - Offers the ability to access cross-sectional knowledge more easily - Written by expert researchers in biogerontology who are actively involved in various fields within aging research

There is perhaps no other single technology or industry subsector, with the exception of AI, that has more potential to accelerate the realization of real-world impacts in Longevity across the full scope of its sectors and domains - industry, policy, investment, entrepreneurship, policy, and governance - than Biomarkers of Human Longevity. Given the unique confluence of Biomarkers of Human Longevity's disruptive impact and accelerative potential, on the one hand, and the high degree of disharmonization in terms of what they are and how they could and should be used, on the other hand, it is clear to me that there is a pressing unmet need for the production of a dedicated book that takes Biomarkers of Longevity as its central concern and major fulcrum, identifying the true potential that this technology has to increase individual and national Health-Adjusted Life Expectancy (HALE) and Quality-Adjusted Life Expectancy (QALY), optimize strategic decision-making for start-ups and corporations, de-risk investment, provide for the first time a tangible framework for company valuation, due diligence based on human validation, enable reliable forecasting clinical outcomes, serve as an effective platform for safe self-experimentation and personalized therapeutic fine-tuning, and pave the way for a much more tangible, stable and scalable Global Longevity Industry, where Longevity's socially-inclusive humanitarian impact is maximized and its potential ethical and socioeconomic concerns are neutralized. Deep Knowledge Group and its Longevity-focused subsidiaries and affiliates, including its analytical subsidiary Aging Analytics Agency, its specialized investment arm Longevity.Capital, its portfolio companies Longevity Banking Card and Longevity Financial Advisors and the international non-profit consortium Longevity.International, have prioritized the pressing need and the extreme potential of Biomarkers of Human Longevity (and integrated them in various ways into its overall scope of activities and strategic agenda) for several years now, and are expertly positioned to provide a tangible understanding of the major challenges and opportunities to be faced within this domain, and how they can be applied by individuals, institutions and even entire governments in order to achieve their maximum benefits while neutralizing potential pitfalls and issues.

Recent studies have indicated that epigenetic processes may play a major role in both cellular and organismal aging. These epigenetic processes include not only DNA methylation and histone modifications, but also extend to many other epigenetic mediators such as the polycomb group proteins, chromosomal position effects, and noncoding RNA. The topics of this book range from fundamental changes in DNA methylation in aging to the most recent research on intervention into epigenetic modifications to modulate the aging process. The major topics of epigenetics and aging covered in this book are: 1) DNA methylation and histone modifications in aging; 2) Other epigenetic processes and aging; 3) Impact of epigenetics on aging; 4) Epigenetics of age-related diseases; 5) Epigenetic interventions and aging: and 6) Future directions in epigenetic aging research. The most studied of epigenetic processes, DNA methylation, has been associated with cellular aging and aging of organisms for many years. It is now apparent that both global and gene-specific alterations occur not only in DNA methylation during aging, but also in several histone alterations. Many epigenetic alterations can have an impact on aging processes such as stem cell aging, control of telomerase, modifications of telomeres, and epigenetic drift can impact the aging process as evident in the recent studies of aging monozygotic twins. Numerous age-related diseases are affected by epigenetic mechanisms. For example, recent studies have shown that DNA methylation is altered in Alzheimer’s disease and autoimmunity. Other prevalent diseases that have been associated with age-related epigenetic changes include cancer and diabetes. Paternal age and epigenetic changes appear to have an effect on schizophrenia and epigenetic silencing has been associated with several of the progeroid syndromes of premature aging. Moreover, the impact of dietary or drug intervention into epigenetic processes as they affect normal aging or age-related diseases is becoming increasingly feasible.

Biosocial Surveys analyzes the latest research on the increasing number of multipurpose household surveys that collect biological data along with the more familiar interviewerâ€"respondent information. This book serves as a follow-up to the 2003 volume, Cells and Surveys: Should Biological Measures Be Included in Social Science Research? and asks these questions: What have the social sciences, especially demography, learned from those efforts and the greater interdisciplinary communication that has resulted from them? Which biological or genetic information has proven most useful to researchers? How can better models be developed to help integrate biological and social science information in ways that can broaden scientific understanding? This volume contains a collection of 17 papers by distinguished experts in demography, biology, economics, epidemiology, and survey methodology. It is an invaluable sourcebook for social and behavioral science researchers who are working with biosocial data.

The world population is rapidly aging—it is estimated that by 1950, around 17% of the population will be elderly. In this context, aging involves several physiological, psychological and highly complex social processes that vary from one person to another. For a long time, medical care for older adults has focused on treating chronic, age-related diseases and their associated consequences. Recently, biomedical research brings a novel point of view to develop more effective interventions by targeting the aging process itself rather than separate conditions. There is a growing number of reports indicating that aging is driven by several interconnected mechanisms and biological components referred to as the molecular pillars of aging. Interfering with these mechanisms could help to treat, prevent, and understand the development of age-related diseases and associated syndromes. This book provides a clinical perspective and general update on biomedical and genetic research in aging, moving from an update in the molecular pillars of aging to a perspective of the most recent pharmacological, clinical, and diagnostic applications using genomic approaches and techniques. While this book focuses on the specifics of genetics and genomics, it also adopts a clinical perspective of geroscience, which seeks to understand the genetic, molecular and cellular mechanisms that make aging an important risk factor and, sometimes, a determining factor in the diseases and common chronic conditions of older people. Additionally, Clinical Genetics and Genomics of Aging is a significant contribution to support aging research, as it shows that collaboration across disciplines is relevant to progress in the field. As more and more people benefit from increased longevity, clinician and researchers will be empowered by this knowledge to contribute to the progress of aging research.